Lynn Markowitz
Johnson & Johnson (United States)(US)Johnson & Johnson (Israel)(IL)
Publications by Year
Research Areas
Monoclonal and Polyclonal Antibodies Research, Immunodeficiency and Autoimmune Disorders, Glycosylation and Glycoproteins Research, Chronic Lymphocytic Leukemia Research, T-cell and B-cell Immunology
Most-Cited Works
- → M281, an Anti‐FcRn Antibody: Pharmacodynamics, Pharmacokinetics, and Safety Across the Full Range of IgG Reduction in a First‐in‐Human Study(2018)142 cited
- → Elucidating the interplay between IgG-Fc valency and FcγR activation for the design of immune complex inhibitors(2016)65 cited
- → Nipocalimab, an immunoselective FcRn blocker that lowers IgG and has unique molecular properties(2025)20 cited
- → An optimized IL-12-Fc expands its therapeutic window, achieving strong activity against mouse tumors at tolerable drug doses(2023)17 cited
- → M281: A Therapeutic Anti-FcRn Blocking Antibody for Rapid Clearance of IgG and IgG Autoantibodies in Immune Cytopenias and Other Auto/Allo-Immune Disease(2015)9 cited
- → Abstract 1714: Preclinical characterization of DF6002/BMS-986415, a novel differentiated IL-12 Fc-fusion protein with robust antitumor activity as monotherapy or in combination with anti-PD-1(2021)5 cited
- → THU0057 Targeting the Neonatal FC Receptor (FCRN) to Mediate Autoantibody Clearance in IgG-Driven Autoimmune Disease(2015)1 cited
- → OP0197 High-Resolution, Integrated Molecular Profiling Reveals Persistent Inflammation in Kawasaki Disease Patients with Coronary Artery Aneurysms(2015)